Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

Completed

Conditions studied: Advanced Melanoma

In brief

The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy

Key facts

Study ID

NCT07079644

Run by

Bristol-Myers Squibb

People needed

678

Starts

2024-11-29

Expected to finish

2025-03-31

Last updated by the study team

2025-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants in the advanced melanoma cohort
• Participants included in the cohort by Flatiron criteria of: cutaneous melanoma with pathologic stages III or IV, either at initial diagnosis or via local or distant recurrence, and at least two clinic encounters evident in the database
• Participants receiving Nivolumab + Relatlimab between March 18, 2022 and September 30, 2024 or other therapies (Nivolumab + Ipilimumab, immunotherapy monotherapy, BRAF/MEK inhibitors) between March 18, 2022 and November 30, 2024 (or date of the most recent data cut off)
• Participants ≥18 years old on index date
• Participants with ≥1 month of medical data after the index date (inclusive), unless patient died within this period

You may not qualify if…

• Participants with diagnosis of other primary cancers prior to the index date
• Participants receiving medication in a clinical trial at any time prior to, on or after index date

Where it is running

• Bristol Myers Squibb — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.